Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial



Fennell, Dean A, Ewings, Sean, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Califano, Raffaele, Hanna, Gerard G, Hill, Kayleigh, Danson, Sarah, Steele, Nicola, Nye, Mavis, Johnson, Lucy
et al (show 12 more authors) (2021) Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. LANCET ONCOLOGY, 22 (11). 1530 - 1540.

[img] Text
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM) a multicentre, double-blind, randomised,.pdf - OA Published Version

Download (617kB) | Preview
Item Type: Article
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 22 Dec 2021 09:41
Last Modified: 10 Sep 2022 12:14
DOI: 10.1016/S1470-2045(21)00471-X
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3145785